Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial Dr Valerie J Page, MBBCh, Prof E Wesley Ely, MD, Prof Simon Gates, PhD, Xiao Bei Zhao, RN, Timothy Alce, PhD, Ayumi Shintani, PhD, Jim Jackson, PsyD, Prof Gavin D Perkins, MD, Prof Daniel F McAuley, MD The Lancet Respiratory Medicine Volume 1, Issue 7, Pages 515-523 (September 2013) DOI: 10.1016/S2213-2600(13)70166-8 Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile *20 patients had more than one reason for exclusion. The Lancet Respiratory Medicine 2013 1, 515-523DOI: (10.1016/S2213-2600(13)70166-8) Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 2 Proportion of study patients with resolution of delirium over time The Lancet Respiratory Medicine 2013 1, 515-523DOI: (10.1016/S2213-2600(13)70166-8) Copyright © 2013 Elsevier Ltd Terms and Conditions
Figure 3 Study patients with agitation in first 14 days The Lancet Respiratory Medicine 2013 1, 515-523DOI: (10.1016/S2213-2600(13)70166-8) Copyright © 2013 Elsevier Ltd Terms and Conditions